Role of Rapid Antigen Testing in Population-Based SARS-CoV-2 Screening

This study evaluates a population-based screening of asymptomatic people, using a rapid antigen diagnostic test (RADT), in areas of high transmission. To detect sources of SARS-CoV-2 infection, nasopharyngeal samples were taken and were tested using RADT. Confirmatory RT-qPCR tests were performed in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2021-08, Vol.10 (17), p.3854
Hauptverfasser: Martín-Sánchez, Vicente, Fernández-Villa, Tania, Carvajal Urueña, Ana, Rivero Rodríguez, Ana, Reguero Celada, Sofía, Sánchez Antolín, Gloria, Fernández-Vázquez, José Pedro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 17
container_start_page 3854
container_title Journal of clinical medicine
container_volume 10
creator Martín-Sánchez, Vicente
Fernández-Villa, Tania
Carvajal Urueña, Ana
Rivero Rodríguez, Ana
Reguero Celada, Sofía
Sánchez Antolín, Gloria
Fernández-Vázquez, José Pedro
description This study evaluates a population-based screening of asymptomatic people, using a rapid antigen diagnostic test (RADT), in areas of high transmission. To detect sources of SARS-CoV-2 infection, nasopharyngeal samples were taken and were tested using RADT. Confirmatory RT-qPCR tests were performed in both positive and negative cases. The internal validity of the RADT, the prevalence of infection, and the positive and negative predictive values (PPV and NPV) were estimated, based on the percentages of confirmed cases with 95% confidence interval. Of the 157,920 people registered, 50,492 participated in the screening; 50,052 were negative, and 440 were positive on the RADT (0.87%). A total of 221 positive RADT samples were reanalysed using RT-qPCR and 214 were confirmed as positive (96.8%; 95% CI: 93.5-98.7%), while 657 out of 660 negative RADT samples were confirmed as RT-qPCR negative (99.5%; 95% CI 98.7-99.9%). The sensitivity obtained was 65.1% (38.4-90.2%) and the specificity was 99.97% (99.94-99.99%). The prevalence of infection was 1.30% (0.95-2.13%). The PPVs were 95.4% (85.9-98.9%) and 97.9% (93.3-99.5%), respectively, while the NPVs were 99.7% (99.4-100%) and 99.2% (98.7-100%), respectively. The high specificity found allow us to report a high screening performance in asymptomatic patients, even in areas where the prevalence of infection was less than 2%.
doi_str_mv 10.3390/jcm10173854
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8432187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2571921240</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-af2b7e9873faec6a1687b2fa974c0736c63547b5bded19dc8308a06ae1b6cae73</originalsourceid><addsrcrecordid>eNpdkc1Lw0AQxRdRbKk9eZeAF0Gi-5FkNxehFquCoLTV67LZTOqWdDdmE8H_3tTWUp3LDMyPx3s8hE4JvmIsxddLvSKYcCbi6AD1KeY8xEyww727h4beL3E3QkSU8GPUY1GMCU15H02mroTAFcFUVSYPRrYxC7DBHHxj7CIwNnhxVVuqxjgb3ioPeTAbTWfh2L2FNJjpGsB24Ak6KlTpYbjdA_Q6uZuPH8Kn5_vH8egp1BFOm1AVNOOQCs4KBTpRJBE8o4VKeaQxZ4lOWBzxLM5yyEmaa8GwUDhRQLJEK-BsgG42ulWbrSDXYJtalbKqzUrVX9IpI_9-rHmXC_cpRcQoEWuBi61A7T7aLqVcGa-hLJUF13pJY05SSmiEO_T8H7p0bW27eD8UIwklSUddbihdO-9rKHZmCJbriuReRR19tu9_x_4Wwr4B98SK3w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2571316216</pqid></control><display><type>article</type><title>Role of Rapid Antigen Testing in Population-Based SARS-CoV-2 Screening</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Martín-Sánchez, Vicente ; Fernández-Villa, Tania ; Carvajal Urueña, Ana ; Rivero Rodríguez, Ana ; Reguero Celada, Sofía ; Sánchez Antolín, Gloria ; Fernández-Vázquez, José Pedro</creator><creatorcontrib>Martín-Sánchez, Vicente ; Fernández-Villa, Tania ; Carvajal Urueña, Ana ; Rivero Rodríguez, Ana ; Reguero Celada, Sofía ; Sánchez Antolín, Gloria ; Fernández-Vázquez, José Pedro</creatorcontrib><description>This study evaluates a population-based screening of asymptomatic people, using a rapid antigen diagnostic test (RADT), in areas of high transmission. To detect sources of SARS-CoV-2 infection, nasopharyngeal samples were taken and were tested using RADT. Confirmatory RT-qPCR tests were performed in both positive and negative cases. The internal validity of the RADT, the prevalence of infection, and the positive and negative predictive values (PPV and NPV) were estimated, based on the percentages of confirmed cases with 95% confidence interval. Of the 157,920 people registered, 50,492 participated in the screening; 50,052 were negative, and 440 were positive on the RADT (0.87%). A total of 221 positive RADT samples were reanalysed using RT-qPCR and 214 were confirmed as positive (96.8%; 95% CI: 93.5-98.7%), while 657 out of 660 negative RADT samples were confirmed as RT-qPCR negative (99.5%; 95% CI 98.7-99.9%). The sensitivity obtained was 65.1% (38.4-90.2%) and the specificity was 99.97% (99.94-99.99%). The prevalence of infection was 1.30% (0.95-2.13%). The PPVs were 95.4% (85.9-98.9%) and 97.9% (93.3-99.5%), respectively, while the NPVs were 99.7% (99.4-100%) and 99.2% (98.7-100%), respectively. The high specificity found allow us to report a high screening performance in asymptomatic patients, even in areas where the prevalence of infection was less than 2%.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm10173854</identifier><identifier>PMID: 34501297</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age groups ; Antigens ; Asymptomatic ; Clinical medicine ; Contact tracing ; Coronaviruses ; COVID-19 ; COVID-19 diagnostic tests ; Disease transmission ; Infections ; Population ; Severe acute respiratory syndrome coronavirus 2 ; Validity ; Values</subject><ispartof>Journal of clinical medicine, 2021-08, Vol.10 (17), p.3854</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-af2b7e9873faec6a1687b2fa974c0736c63547b5bded19dc8308a06ae1b6cae73</citedby><cites>FETCH-LOGICAL-c409t-af2b7e9873faec6a1687b2fa974c0736c63547b5bded19dc8308a06ae1b6cae73</cites><orcidid>0000-0003-0552-2804 ; 0000-0002-9049-3026</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432187/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432187/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34501297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martín-Sánchez, Vicente</creatorcontrib><creatorcontrib>Fernández-Villa, Tania</creatorcontrib><creatorcontrib>Carvajal Urueña, Ana</creatorcontrib><creatorcontrib>Rivero Rodríguez, Ana</creatorcontrib><creatorcontrib>Reguero Celada, Sofía</creatorcontrib><creatorcontrib>Sánchez Antolín, Gloria</creatorcontrib><creatorcontrib>Fernández-Vázquez, José Pedro</creatorcontrib><title>Role of Rapid Antigen Testing in Population-Based SARS-CoV-2 Screening</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>This study evaluates a population-based screening of asymptomatic people, using a rapid antigen diagnostic test (RADT), in areas of high transmission. To detect sources of SARS-CoV-2 infection, nasopharyngeal samples were taken and were tested using RADT. Confirmatory RT-qPCR tests were performed in both positive and negative cases. The internal validity of the RADT, the prevalence of infection, and the positive and negative predictive values (PPV and NPV) were estimated, based on the percentages of confirmed cases with 95% confidence interval. Of the 157,920 people registered, 50,492 participated in the screening; 50,052 were negative, and 440 were positive on the RADT (0.87%). A total of 221 positive RADT samples were reanalysed using RT-qPCR and 214 were confirmed as positive (96.8%; 95% CI: 93.5-98.7%), while 657 out of 660 negative RADT samples were confirmed as RT-qPCR negative (99.5%; 95% CI 98.7-99.9%). The sensitivity obtained was 65.1% (38.4-90.2%) and the specificity was 99.97% (99.94-99.99%). The prevalence of infection was 1.30% (0.95-2.13%). The PPVs were 95.4% (85.9-98.9%) and 97.9% (93.3-99.5%), respectively, while the NPVs were 99.7% (99.4-100%) and 99.2% (98.7-100%), respectively. The high specificity found allow us to report a high screening performance in asymptomatic patients, even in areas where the prevalence of infection was less than 2%.</description><subject>Age groups</subject><subject>Antigens</subject><subject>Asymptomatic</subject><subject>Clinical medicine</subject><subject>Contact tracing</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 diagnostic tests</subject><subject>Disease transmission</subject><subject>Infections</subject><subject>Population</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Validity</subject><subject>Values</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc1Lw0AQxRdRbKk9eZeAF0Gi-5FkNxehFquCoLTV67LZTOqWdDdmE8H_3tTWUp3LDMyPx3s8hE4JvmIsxddLvSKYcCbi6AD1KeY8xEyww727h4beL3E3QkSU8GPUY1GMCU15H02mroTAFcFUVSYPRrYxC7DBHHxj7CIwNnhxVVuqxjgb3ioPeTAbTWfh2L2FNJjpGsB24Ak6KlTpYbjdA_Q6uZuPH8Kn5_vH8egp1BFOm1AVNOOQCs4KBTpRJBE8o4VKeaQxZ4lOWBzxLM5yyEmaa8GwUDhRQLJEK-BsgG42ulWbrSDXYJtalbKqzUrVX9IpI_9-rHmXC_cpRcQoEWuBi61A7T7aLqVcGa-hLJUF13pJY05SSmiEO_T8H7p0bW27eD8UIwklSUddbihdO-9rKHZmCJbriuReRR19tu9_x_4Wwr4B98SK3w</recordid><startdate>20210827</startdate><enddate>20210827</enddate><creator>Martín-Sánchez, Vicente</creator><creator>Fernández-Villa, Tania</creator><creator>Carvajal Urueña, Ana</creator><creator>Rivero Rodríguez, Ana</creator><creator>Reguero Celada, Sofía</creator><creator>Sánchez Antolín, Gloria</creator><creator>Fernández-Vázquez, José Pedro</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0552-2804</orcidid><orcidid>https://orcid.org/0000-0002-9049-3026</orcidid></search><sort><creationdate>20210827</creationdate><title>Role of Rapid Antigen Testing in Population-Based SARS-CoV-2 Screening</title><author>Martín-Sánchez, Vicente ; Fernández-Villa, Tania ; Carvajal Urueña, Ana ; Rivero Rodríguez, Ana ; Reguero Celada, Sofía ; Sánchez Antolín, Gloria ; Fernández-Vázquez, José Pedro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-af2b7e9873faec6a1687b2fa974c0736c63547b5bded19dc8308a06ae1b6cae73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age groups</topic><topic>Antigens</topic><topic>Asymptomatic</topic><topic>Clinical medicine</topic><topic>Contact tracing</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 diagnostic tests</topic><topic>Disease transmission</topic><topic>Infections</topic><topic>Population</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Validity</topic><topic>Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martín-Sánchez, Vicente</creatorcontrib><creatorcontrib>Fernández-Villa, Tania</creatorcontrib><creatorcontrib>Carvajal Urueña, Ana</creatorcontrib><creatorcontrib>Rivero Rodríguez, Ana</creatorcontrib><creatorcontrib>Reguero Celada, Sofía</creatorcontrib><creatorcontrib>Sánchez Antolín, Gloria</creatorcontrib><creatorcontrib>Fernández-Vázquez, José Pedro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martín-Sánchez, Vicente</au><au>Fernández-Villa, Tania</au><au>Carvajal Urueña, Ana</au><au>Rivero Rodríguez, Ana</au><au>Reguero Celada, Sofía</au><au>Sánchez Antolín, Gloria</au><au>Fernández-Vázquez, José Pedro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of Rapid Antigen Testing in Population-Based SARS-CoV-2 Screening</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2021-08-27</date><risdate>2021</risdate><volume>10</volume><issue>17</issue><spage>3854</spage><pages>3854-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>This study evaluates a population-based screening of asymptomatic people, using a rapid antigen diagnostic test (RADT), in areas of high transmission. To detect sources of SARS-CoV-2 infection, nasopharyngeal samples were taken and were tested using RADT. Confirmatory RT-qPCR tests were performed in both positive and negative cases. The internal validity of the RADT, the prevalence of infection, and the positive and negative predictive values (PPV and NPV) were estimated, based on the percentages of confirmed cases with 95% confidence interval. Of the 157,920 people registered, 50,492 participated in the screening; 50,052 were negative, and 440 were positive on the RADT (0.87%). A total of 221 positive RADT samples were reanalysed using RT-qPCR and 214 were confirmed as positive (96.8%; 95% CI: 93.5-98.7%), while 657 out of 660 negative RADT samples were confirmed as RT-qPCR negative (99.5%; 95% CI 98.7-99.9%). The sensitivity obtained was 65.1% (38.4-90.2%) and the specificity was 99.97% (99.94-99.99%). The prevalence of infection was 1.30% (0.95-2.13%). The PPVs were 95.4% (85.9-98.9%) and 97.9% (93.3-99.5%), respectively, while the NPVs were 99.7% (99.4-100%) and 99.2% (98.7-100%), respectively. The high specificity found allow us to report a high screening performance in asymptomatic patients, even in areas where the prevalence of infection was less than 2%.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34501297</pmid><doi>10.3390/jcm10173854</doi><orcidid>https://orcid.org/0000-0003-0552-2804</orcidid><orcidid>https://orcid.org/0000-0002-9049-3026</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof Journal of clinical medicine, 2021-08, Vol.10 (17), p.3854
issn 2077-0383
2077-0383
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8432187
source PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Age groups
Antigens
Asymptomatic
Clinical medicine
Contact tracing
Coronaviruses
COVID-19
COVID-19 diagnostic tests
Disease transmission
Infections
Population
Severe acute respiratory syndrome coronavirus 2
Validity
Values
title Role of Rapid Antigen Testing in Population-Based SARS-CoV-2 Screening
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T03%3A00%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20Rapid%20Antigen%20Testing%20in%20Population-Based%20SARS-CoV-2%20Screening&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Mart%C3%ADn-S%C3%A1nchez,%20Vicente&rft.date=2021-08-27&rft.volume=10&rft.issue=17&rft.spage=3854&rft.pages=3854-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm10173854&rft_dat=%3Cproquest_pubme%3E2571921240%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2571316216&rft_id=info:pmid/34501297&rfr_iscdi=true